Last reviewed · How we verify
Diphenhydramine 5%
Diphenhydramine 5% is a H1 receptor antagonist (first-generation antihistamine) Small molecule drug developed by Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology. It is currently FDA-approved for Allergic reactions and urticaria, Pruritus (itching), Allergic rhinitis.
Diphenhydramine is a first-generation antihistamine that blocks H1 histamine receptors to reduce allergic and inflammatory responses.
Diphenhydramine is a first-generation antihistamine that blocks H1 histamine receptors to reduce allergic and inflammatory responses. Used for Allergic reactions and urticaria, Pruritus (itching), Allergic rhinitis.
At a glance
| Generic name | Diphenhydramine 5% |
|---|---|
| Sponsor | Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology |
| Drug class | H1 receptor antagonist (first-generation antihistamine) |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Diphenhydramine competitively antagonizes H1 histamine receptors on various tissues, preventing histamine-mediated effects such as itching, urticaria, and allergic reactions. As a first-generation antihistamine, it crosses the blood-brain barrier and also possesses anticholinergic and sedating properties due to central nervous system penetration.
Approved indications
- Allergic reactions and urticaria
- Pruritus (itching)
- Allergic rhinitis
- Motion sickness and nausea
Common side effects
- Drowsiness/sedation
- Dry mouth
- Dizziness
- Anticholinergic effects (urinary retention, constipation)
Key clinical trials
- Trial of Zolpidem for Sleep in Children With Autism (PHASE2)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (PHASE1, PHASE2)
- Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms (PHASE4)
- Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment (PHASE1)
- Tazemetostat and Palbociclib With CPX-351for R/R AML (PHASE1)
- Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma (PHASE2)
- TReatment for ImmUne Mediated PathopHysiology (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diphenhydramine 5% CI brief — competitive landscape report
- Diphenhydramine 5% updates RSS · CI watch RSS
- Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology portfolio CI
Frequently asked questions about Diphenhydramine 5%
What is Diphenhydramine 5%?
How does Diphenhydramine 5% work?
What is Diphenhydramine 5% used for?
Who makes Diphenhydramine 5%?
What drug class is Diphenhydramine 5% in?
What development phase is Diphenhydramine 5% in?
What are the side effects of Diphenhydramine 5%?
What does Diphenhydramine 5% target?
Related
- Drug class: All H1 receptor antagonist (first-generation antihistamine) drugs
- Target: All drugs targeting H1 histamine receptor
- Manufacturer: Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology — full pipeline
- Therapeutic area: All drugs in Allergy/Immunology
- Indication: Drugs for Allergic reactions and urticaria
- Indication: Drugs for Pruritus (itching)
- Indication: Drugs for Allergic rhinitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing